Tirzepatide explained: how it differs from GLP-1 medicines

Tirzepatide is a medicine that activates two gut-hormone receptors, GIP and GLP-1. Semaglutide, liraglutide and similar medicines activate only the GLP-1 receptor. Zepbound is FDA-approved for weight reduction and obstructive sleep apnea in adults with obesity, and Mounjaro for type 2 diabetes. In one direct comparison in adults with obesity, average weight loss was larger with tirzepatide, though that does not decide what is right for an individual.

Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)

Quick answer

Tirzepatide is a medicine that activates two gut-hormone receptors, GIP and GLP-1. Semaglutide, liraglutide and similar medicines activate only the GLP-1 receptor. Zepbound is FDA-approved for weight reduction and obstructive sleep apnea in adults with obesity, and Mounjaro for type 2 diabetes. In one direct comparison in adults with obesity, average weight loss was larger with tirzepatide, though that does not decide what is right for an individual.

Terms

An incretin is a gut hormone released after eating. A receptor is the docking site a hormone or drug acts on. GIP and GLP-1 are two incretins. Zepbound and Mounjaro are brand names; the generic name is tirzepatide. Wegovy and Ozempic are brands of semaglutide.

How the labels describe it

The Zepbound label says tirzepatide is a GIP and GLP-1 receptor agonist. It says GLP-1 is a physiological regulator of appetite and caloric intake, and that nonclinical studies suggest adding GIP may further contribute to the regulation of food intake. Both receptors are found in brain areas involved in appetite regulation. Source: Zepbound label, section 12.1.

ProductActive ingredientApproved uses (adults unless noted)
ZepboundTirzepatideWeight reduction and long-term maintenance with obesity, or overweight plus a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity
MounjaroTirzepatideBlood-sugar control in type 2 diabetes (adults and patients 10+); lower risk of major cardiovascular events in type 2 diabetes at high risk

The Zepbound label says coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. Mounjaro’s label is here.

What the studies show

Tirzepatide trial results

Tirzepatide trial results

Against placebo (SURMOUNT-1). In 2,539 adults with obesity (or overweight plus a weight-related condition) without diabetes, 72 weeks of weekly tirzepatide gave mean weight changes of -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg), versus -3.1% with placebo. Source: Jastreboff et al., NEJM 2022, doi:10.1056/NEJMoa2206038.

Direct comparison with semaglutide (SURMOUNT-5). In 751 adults with obesity without diabetes, in an open-label trial, participants took the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Mean weight change was -20.2% versus -13.7% (P<0.001); waist circumference fell 18.4 cm versus 13.0 cm. Source: Aronne et al., NEJM 2025, doi:10.1056/NEJMoa2416394.

Type 2 diabetes (SURPASS-2). In an open-label, 40-week trial of 1,879 adults with type 2 diabetes, tirzepatide 5, 10 and 15 mg lowered HbA1c more than semaglutide 1 mg (differences versus semaglutide of -0.15 percentage points at 5 mg and -0.39 at 10 mg; the 15 mg group also had a larger reduction). This used semaglutide 1 mg, a diabetes dose, not 2.4 mg. Source: Frias et al., NEJM 2021, doi:10.1056/NEJMoa2107519.

What the evidence cannot tell you

  • SURMOUNT-5 is a direct comparison, but it was open-label (participants and staff knew the treatment), and it reports averages.
  • Larger average weight loss does not mean one medicine is better for you. Tolerability, other conditions, cost, coverage, supply and preference matter, and these are not settled by a trial average.
  • Whether to change from one medicine to another is a prescriber decision. For questions to bring to your prescriber, read changing medication or route.
  • Results in people with diabetes or sleep apnea are separate questions with their own trials.

Safety signposts

Like semaglutide, tirzepatide carries a boxed warning about thyroid C-cell tumors in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. The label says it is not recommended in severe gastroparesis and lists severe gastrointestinal reactions. Source: Zepbound label.

FAQs

What is tirzepatide? A once-weekly injection that activates GIP and GLP-1 receptors, sold as Zepbound and Mounjaro.

What does human research show about tirzepatide? SURMOUNT-1: mean weight change of -15.0% to -20.9% by dose at 72 weeks vs -3.1% placebo. SURMOUNT-5: -20.2% vs -13.7% for semaglutide.

What safety or regulatory questions remain? Long-term effects, individual response, and how non-approved versions are made and sold. Talk with a licensed clinician.

Sources

  1. FDA label, Zepbound
  2. FDA label, Mounjaro
  3. Jastreboff et al., SURMOUNT-1, NEJM 2022
  4. Aronne et al., SURMOUNT-5, NEJM 2025
  5. Frias et al., SURPASS-2, NEJM 2021